Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cribriform Gleason pattern 4: active surveillance no more?

BJU international·2026
Same author

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

The Journal of clinical investigation·2026
Same author

High Frequency Loss of 17q11.2 and Downregulation of the Cancer Metastasis Suppression microRNA miR-193a-3p in Prostate Cancer Bone Metastasis.

Cancers·2026
Same author

Somatic Tumor-Like Neoplasms Arising With Testicular Germ Cell Tumors: Distilling Evolving Understanding, Terminology, and Implications for the Practicing Surgical Pathologist.

Advances in anatomic pathology·2026
Same author

Frozen section is unnecessary for diagnosis in partial orchidectomy specimens.

Histopathology·2026
Same author

The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate.

Histopathology·2025
Same journal

Cardiotoxicity, survival, and dexrazoxane use in patients with soft tissue sarcoma: a Danish population‑based cohort study.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Overall survival following palliative immune checkpoint inhibitor treatment according to ECOG performance status: a large registry-based study.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Recent survival trends in the most fatal cancers in the Nordic countries: gains in some but not in all.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

First-in-human quantitative [¹⁵O]H₂O PET imaging of tumour blood flow at rest and during exercise in lymphoma patients.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Starshot field configuration in the linac isocentre size determination: a comparison of film and electronic portal imaging device measurements.

Acta oncologica (Stockholm, Sweden)·2026
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Pathology in prostate research: optimizing the pathological data.

Daniel M Berney1, Rodolfo Montironi, Lars Egevad

  • 1Department of Molecular Oncology and Imaging, Institute of Cancer, Queen Mary University of London, London, UK. D.Berney@bartsandthelondon.nhs.uk

Acta Oncologica (Stockholm, Sweden)
|May 25, 2011
PubMed
Summary
This summary is machine-generated.

Standardizing prostate cancer pathology diagnoses and grading criteria is crucial. This ensures reliable data for clinical trials and accurate biomarker evaluation, improving patient prognoses.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol
09:04

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol

Published on: November 14, 2025

Related Experiment Videos

Last Updated: Jun 1, 2026

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol
09:04

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol

Published on: November 14, 2025

Area of Science:

  • Oncology
  • Pathology
  • Medical Diagnostics

Background:

  • Pathology is the gold standard for prostate cancer diagnosis, staging, and grading.
  • Variations in national standards and protocols can lead to intra-observer variability.
  • This variability impacts data quality in clinical trials and biomarker research.

Purpose of the Study:

  • To highlight the need for standardization in prostate cancer pathology.
  • To address the impact of diagnostic and grading variations on research.
  • To emphasize the importance of accurate tumor measurements and staging criteria.

Main Methods:

  • Review of current diagnostic and grading criteria in prostate cancer pathology.
  • Analysis of the impact of historical changes in Gleason grading.
  • Examination of tumor measurement and staging criteria in biopsy and radical prostatectomy specimens.

Main Results:

  • Diagnostic error rates have improved but remain a concern.
  • Changes in Gleason grading over time may affect research cohort accuracy.
  • Standardization of tumor extent measures and staging criteria is necessary for improved prognostic assessment.

Conclusions:

  • Standardized pathological assessment is vital for robust clinical trials.
  • Accurate utilization of pathological material enhances the rigor of new biomarker testing.
  • Improved standardization will lead to more reliable prognostic information for prostate cancer patients.